Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?
Answer from: Medical Oncologist at Community Practice
Toxicity with Neuropathy can be a major problem in the elderly population.
Sign in or Register to read more
5102
Related Questions
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
How do you decide whether to add docetaxel to ADT/abiraterone or ADT/darolutamide in patients with mCSPC in the era of PSMA PET staging?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?